The constituent drugs are indicated for the same disease, but may exert different therapeutic effects via disparate mechanisms of action.
Some examples of codrugs include:
- Sulfasalazine, which is a combination of sulfapyridine and 5-aminosalicylic acid coupled with an azo linkage
- Benorylate, which is an esterified product of paracetamol and acetylsalicylic acid
- Sultamicillin, which is an ester of ampicillin and sulbactam
- Fenethylline, which is a combination of amphetamine and theophylline
An effective codrug should be pharmacologically inactive in its own right, but should release the constituent drugs upon biochemical breakage of the chemical linkage at the target tissue where their therapeutic effects are needed. As such, the chemical linkage (usually a covalent bond) should be subjectable to biodegradation, such as hydrolysis, by an enzymatic or non-enzymatic mechanism. The differential distribution of enzymes capable of catalyzing the breakage of the chemical linkage in different tissues may be exploited to achieve tissue-specific metabolism of the codrug to release the constituent drugs.
- W. M. Lau (2008). "Scope and Limitations of the Co-Drug Approach to Topical Drug Delivery". Current Pharmaceutical Design. 14 (8): 794–802. doi:10.2174/138161208784007653. PMID 18393881.
- N. Das (2010). "Codrug: An efficient approach for drug optimization" (PDF). European Journal of Pharmaceutical Sciences. 41 (5): 571–588. doi:10.1016/j.ejps.2010.09.014.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|